What You Should Know:
– GrayMatters Health (GMH), a pioneer in digital brain biomarker-based mental health treatments, is broadening patient access to its Prism for PTSD™ therapy.
– As the first FDA-cleared self-neuromodulation device for post-traumatic stress disorder (PTSD), Prism for PTSD™ offers a new approach to managing this debilitating condition.
Prism for PTSD™: A Personalized Approach to Healing
GMH’s patented technology utilizes an amygdala-based biomarker to guide patients in regulating brain activity associated with PTSD. This self-neuromodulation approach empowers patients to actively participate in their healing process. Prism for PTSD™ is now available in clinics across the U.S., empowering patients to learn how to regulate brain activity associated with PTSD symptoms. This personalized and engaging therapy utilizes a unique approach based on proprietary digital biomarkers of brain regions linked to mental disorders.
Several of the new clinics offering Prism include Breakthru Psychiatric Solutions (Sandy Springs and Alpharetta, GA), Forensic & Clinical Psychiatry (Seattle, WA), and Institute for Advanced Psychiatry (Fort Worth, TX).
Proven Effectiveness and Safety
In a pivotal clinical trial published in the Journal of Psychiatry Research, Prism for PTSD™ demonstrated impressive results:
- Significant Symptom Improvement: 67% of patients experienced clinically significant improvement in their PTSD symptoms.
- High Response Rates: Response rates exceeded 80% in certain sub-populations.
- Minimal Side Effects: Mild and transient side effects, such as headaches and fatigue, resolved without intervention.
- Broad Impact: A new analysis presented at the International Society for Traumatic Stress Studies showed significant effects across all PTSD symptom clusters.
